The direct oral anticoagulants (DOACs) (apixaban, rivaroxaban, betrixaban, edoxaban and dabigatran) have gradually replaced vitamin K antagonists (VKAs) as the mainstay anticoagulation therapy. However, lack of specific reversal agents has been consistently raised as a concern since the introduction of the DOACs. Major bleeding and invasive procedures are common clinical settings where DOAC reversal may be required; further a high frequency of co-morbid conditions makes it likely that patients treated with DOACs will require such interruptions of their therapy.
